CD200 and AL amyloidosis: Mahadevan et al. (2019) published the results of their phase I clinical trial where they administered a novel recombinant humanized monoclonal antibody called Samalizumab that blocks CD200 in chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) patients.